Arrow In this section

Future cancer genomics testing will align to the NHSE National Genomic Test Directory (NTD) for Cancer.

It is anticipated that non-WGS standard-of-care testing will be delivered by multiple testing pathways, with the majority of routine cancer referrals being processed by pan-cancer NGS panel workflows (DNA, RNA or both as required).

To maximise efficiency and cost effectiveness the routine pan-cancer NGS panel pathway will be centralised to a single site within each GLH offering appropriate automated enrichment and high throughput sequencing platforms.